Brain Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Response to Antidepressants Treatment in Major Depression
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 188
- 试验地点
- 2
- 主要终点
- Score on Montgomery and Asberg Depression Rating Scale (MADRS)
研究概览
简要总结
The main hypothesis is that the therapeutic response and pharmacological resistance to ADs in depressed patients can be associated with a polymorphism for the BDNF gene. The research of allelic forms associated to lesser efficiency or inefficiency of ADs could add to the body of evidence that BDNF mediates the mechanism of action of ADs, and could have important practical implications. We propose to compare in a group of patients with major depression, the allelic variability of the BDNF gene between responders and non-responders after a 3-week period and a 6-week period of SSRI treatment.
详细描述
- The main objective is to research an association between polymorphism for the BDNF gene and the 3-week and 6-week response to a SSRI treatment (escitalopram) in major depression.
- A case control pilot study without any direct individual benefit (200 patients).
- Study period: 24 months.
- Scores from reliable and validated psychometric scales (Montgomery and Asberg Depression Scale, Mini International Neuropsychiatric Interview) specifically analysing depression dimension at the time of inclusion, after three and six weeks of antidepressant treatment.
- Genetic analysis researching a polymorphism of the BDNF gene is done by a blood sample at the baseline.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient suffering a severe depressive episode (according to DSM-IV), evolving since at least 2 weeks before entering the study
- •Age superior to 18 years
- •Caucasian type
- •In absence of any medicinal treatment that could enhance depression: methyldopa, beta-blockers, reserpine,
- •In absence of hypothyroidia or anaemia
- •Without comorbidity that could affect therapy response : e.g. food disorder, substance abuse or dependence syndrome
排除标准
- •- Will be excluded from the study the patients for which a modification of the depression diagnosis (according to the DSM-IV criteria) takes place during the period of study
研究组 & 干预措施
Escitalopram
Treatment response after 3 and 6 weeks
干预措施: Genetic analysis (Genetic)
结局指标
主要结局
Score on Montgomery and Asberg Depression Rating Scale (MADRS)
时间窗: At 3 weeks and 6 weeks
次要结局
未报告次要终点